Overview

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Status:
RECRUITING

Trial end date:
2030-09-15

Target enrollment:

Participant gender:

Summary

An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal XRT in patients with metastatic solid malignancies.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

atezolizumab
Radiotherapy
Tiragolumab